Half-year trading update
Novacyt S.A. reported a strong first half for 2026, with unaudited statutory revenue increasing by 18% to approximately £11.6 million, driven by 9% organic growth excluding the impact of Southern Cross Diagnostics (SCD). The Instrumentation segment saw 30% revenue growth, and the Clinical segment grew over 20%, with all three geographic regions experiencing year-on-year revenue increases. SCD contributed £1.8 million in revenue since its acquisition. Cash reserves stood at £8.9 million as of June 30, 2026, reflecting a £5.5 million outflow for the SCD acquisition. The company also raised approximately €785,000 gross through a rights issue and is progressing with a restructuring program expected to yield up to £4.0 million in annual cost savings.
Select text to share a quote on X · sign in to keep highlights & notes in your NCYT notes
Paris, France, and Manchester, UK - 28 July 2026 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces its unaudited trading update for the six months ended 30 June 2026.
Financial Highlights
- Unaudited Group statutory revenue for H1 2026 is expected to be up 18% to c. £11.6 million (H1 2025: £9.8 million
o Underlying Group revenue increased by c. 9% (up £0.8 million) excluding the impact of revenue generated from Southern Cross Diagnostics ("SCD"), demonstrating continued organic growth across the business
- The Instrumentation segment delivered c. 30% year-on-year revenue growth, reflecting continued market adoption of the Company's LightBench Discover platform
- The Clinical segment continued its strong momentum delivering more than 20% year-on-year revenue growth, driven by the demand for its NIPT technology and from the inclusion of SCD sales
- All three geographic regions delivered year-on-year revenue growth:
o Americas: >30% growth, driven primarily by strong instrument demand
o Asia-Pacific: c. 22% growth, supported by continued demand for the Company's reproductive health portfolio
o EMEA: c. 2% growth
- SCD contributed c. £1.8 million of revenue during the period from completion of the acquisition on 2 March to 30 June 2026
- Cash at 30 June 2026 was £8.9 million (31 December 2025: £19.1 million). The reduction reflects, amongst other factors, a £5.5 million cash outflow relating to the acquisition of SCD
- Successfully completed a preferential subscription rights issue raising approximately €785,000 gross
Operational Highlights
- The workforce consultation process is progressing and remains ongoing
o The Board still expects up to £4.0 million of annualised cost savings, which will materially reduce the Group's cash burn and strengthen its financial position
- Yourgene Insight DPYD kit, used for the accurate detection of 19 mutations in the DPYD gene for safer chemotherapy treatments, was launched in June 2026 as a Research Use Only assay. IVDR submission is being compiled with IVDR accreditation expected to be granted in the coming months
Commenting on the trading update, Lyn Rees, Chief Executive Officer, said: "We have delivered a strong first half, with robust revenue growth driven by organic momentum alongside the successful integration of Southern Cross Diagnostics, and I am particularly encouraged to see growth across all our regions. We are making good progress with our restructuring programme, which is expected to deliver meaningful cost savings, extending our cash runway and strengthening our financial position."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.